For all donors of convalescent plasma, drop seen in anti-RBD antibody levels from first to last donation

Cumulative incidence of in-hospital mortality estimated to be 37.4 percent at 90 days

Fifty percent of phase 3 clinical trials and 100 percent of vaccine trials at risk for excluding older adults

Risk for dying from breast cancer remains elevated 15 years after initial diagnosis